No­var­tis takes aim at a slate of block­busters with cheap­er biosim­i­lars

No­var­tis stepped in as one of the ear­ly pi­o­neers in de­vel­op­ing new biosim­i­lars. And now the Swiss phar­ma gi­ant has out­lined its game plan to run the ta­ble with 5 new launch­es that will take aim at a slate of bi­o­log­ics that cur­rent­ly ac­count for more than $44 bil­lion in sales.

The gener­ics arm of the com­pa­ny, San­doz, has fil­ings in mind for copy­cat ver­sions of En­brel (etan­er­cept), Hu­mi­ra (adal­i­mum­ab), Neu­las­ta (peg­fil­gras­tim), Rem­i­cade (in­flix­imab) and Rit­ux­an (rit­ux­imab). Al­to­geth­er No­var­tis is on track to com­plete 11 fil­ings – with 5 more to come – run­ning from last year through 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.